Journals / Türk Oftalmoloji Dergisi / 2013 / Cilt: 43 - Sayı: 6

Comparison of corneal endothelial changes after a single-dose ınjection of bevacizumab or ranibizumab

İntravitreal bevacizumab veya ranibizumab enjeksiyonu yapılan olgularda kornea endotelindeki değişimin karşılaştırılması

Pages
391–394
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Dis­cus­si­on: Injection of a single dose of 1.25 mg/0.05 ml bevacizumab or 0.5 mg/0.05 ml ranibizumab does not affect the corneal endothelial cell count at 1. week and 1. month. (Turk J Ophthalmol 2013; 43: 391-4)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pur­po­se: To compare the corneal endothelial changes after injection of a single-dose intravitreal bevacizumab or intravitrearanibizumab.
📊
Key Findings & Data:Ma­te­ri­al and Met­hod: In this retrospective study, we evaluated 27 eyes of 27 patients with either diabetic macular edema or senile macular degeneration, who underwent 1.25 mg/0.05 ml intravitreal bevacizumab or 0.5 mg/0.05 ml ranibizumab injection.
💡
Conclusion & Impact:Dis­cus­si­on: Injection of a single dose of 1.25 mg/0.05 ml bevacizumab or 0.5 mg/0.05 ml ranibizumab does not affect the corneal endothelial cell count at 1. week and 1. month. (Turk J Ophthalmol 2013; 43: 391-4)
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Pur­po­se: To compare the corneal endothelial changes after injection of a single-dose intravitreal bevacizumab or intravitrearanibizumab. Ma­te­ri­al and Met­hod: In this retrospective study, we evaluated 27 eyes of 27 patients with either diabetic macular edema or senile macular degeneration, who underwent 1.25 mg/0.05 ml intravitreal bevacizumab or 0.5 mg/0.05 ml ranibizumab injection. None of the patients had corneal pathology. Fourteen eyes of 14 patients received intravitreal ranibizumab, other 13 eyes of 13 patients received intravitreal bevacizumab. We evaluated preoperative and postoperative 1st week and 1st month visual acuity, corneal endothelial count at mm2, intraocular pressure, and pachymetry results. For statistical analysis, Mann-Whitney U and Wilcoxon tests were used. Re­sults: Mean age of the patients was 69.3±12.5 (44-85 year). Average corneal endothelial cell count for bevacizumab and ranibizumab was preoperatively 2358.1±487 and 2348.9±598, postoperative 1. week 2360.8±474.1 and 2398.3±585.6, postoperative 1. month 2315.1±465 and 2407.4±585.6, respectively. Preoperative and postoperative corneal endothelial cell counts were not statistically significantly different in both groups (respectively, 1. week p=0.953 and p=0.59; 1. month p=0.26 and p=0.555). Average central macular thickness for bevacizumab and ranibizumab was preoperatively 527.3±36.9 and 544.1±55.5 μm, postoperative 1. week 529.2±49.9 and 543.5±51.8 μm, postoperative 1. month 530.3±55 and 543.9±46.6 μm, respectively. Preoperative and postoperative central macular thickness values for both groups were not statistically significantly different (respectively, 1. week P=0.515 and P=0.838; 1. month P=0.678 and P=0.444). Dis­cus­si­on: Injection of a single dose of 1.25 mg/0.05 ml bevacizumab or 0.5 mg/0.05 ml ranibizumab does not affect the corneal endothelial cell count at 1. week and 1. month. (Turk J Ophthalmol 2013; 43: 391-4)

Özet

Amaç: Tek doz intravitreal bevacizumab veya intravitreal ranibizumab enjeksiyonu uygulanan olgularda kornea endotel değişikliklerini karşılaştırmak. Ge­reç ve Yön­tem: Kliniğimiz retina biriminde diyabetik maküla ödemi, yaşa bağlı maküla dejenerasyonu gibi nedenlerle 1,25 mg/0,05 ml intravitreal bevacizumab ya da 0,5 mg/0,05 ml ranibizumab enjeksiyonu yapılan herhangi bir kornea patolojisi olmayan 27 hastanın 27 gözü retrospektif olarak incelendi. Ondört hastanın 14 gözüne intravitreal ranibizumab, diğer 13 hastanın 13 gözüne ise intravitreal bevacizumab enjeksiyonu yapılmıştı. Enjeksiyon öncesi ve postoperatif 1. hafta ve 1. ayda görme keskinliği, mm2deki kornea endotel sayısı, göziçi basıncı, pakimetri ölçüm kayıtları incelendi. İstatistiksel analizlerde Mann-Whitney U ve Wilcoxon testleri kullanıldı. So­nuç­lar: Ortalama yaş 69,3±12,5 (44-85 yıl) idi. Bevacizumab ve ranibizumab gruplarında sırasıyla ortalama kornea endotel sayısı enjeksiyon öncesi 2358,1±487 ve 2348,9±598, enjeksiyon sonrası 1. haftada 2360,8±474,1 ve 2398,3±585,6, enjeksiyon sonrası 1. ayda ise 2315,1±465 ve 2407,4±585,6 idi. Enjeksiyon öncesi ile enjeksiyon sonrası 1. hafta ve 1. ay endotel sayılarındaki değişim her iki grupta da anlamlı bulunmadı (Sırasıyla 1. haftada p=0,953 ve p=0,59; 1. ayda p=0,26 ve p=0,555). Bevacizumab ve ranibizumab gruplarında sırasıyla ortalama merkezi kornea kalınlığı enjeksiyon öncesi 527,3±36,9 ve 544,1±55,5 μm, enjeksiyon sonrası 1. haftada 529,2±49,9 ve 543,5±51,8 μm, enjeksiyon sonrası 1. ayda ise 530,3±55 ve 543,9±46,4 μm idi. Enjeksiyon öncesi ile enjeksiyon sonrası 1. hafta ve 1. ay merkezi kornea kalınlığındaki değişim her iki grupta da anlamlı bulunmadı (Sırasıyla 1. haftada p=0,515 ve p=0,838; 1. ayda p=0,678 ve p=0,444). Tar­t fl­ma: İntravitreal olarak tek doz uygulanan 1,25 mg/0,05 ml bevacizumab ya da 0,5 mg/0,05 ml ranibizumab uygulama sonrası 1. hafta ve 1. ayda kornea endotel sayısında anlamlı bir değişikliğe neden olmamaktadır. (Turk J Ophthalmol 2013; 43: 391-4)

🔖

Cite This Article

KESKİNBORA, K., HOROZOĞLU, F., GÖNEN, T., YAŞAR, M., SEVER, Ö. (2022). Comparison of corneal endothelial changes after a single-dose ınjection of bevacizumab or ranibizumab. Türk Oftalmoloji Dergisi, Cilt: 43 - Sayı: 6, 391–394. https://ajindex.com/articles/638182

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand. 2004;82:557-63
  2. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-22
  3. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999- 1005
  4. Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C. Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration. J Fr Ophtalmol. 2011;34:376-81
  5. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009;93:452-56
  6. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90:1316-21
  7. Luke M, Warga M, Ziemssen F, et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol. 2006;90:1178-82
  8. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-69
  9. Hosny MH, Zayed MA, Shalaby AM, Eissa IM. Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation. J Ocul Pharmacol Ther. 2009;25:513-17
  10. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113:633-34 11. Pérez-Rico C, Benítez-Herreros J, Castro-Rebollo M, et al. Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration. Cornea. 2010;29:849-52
  11. Slakter JS, Bochow TW, D’Amico DJ, et al. Anecortave acetate (15 miligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age related macular degeneration. Ophthalmology. 2006;113:3-13
  12. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA 48 Study): Results of a phase I dose escalation study. Invest Ophthalmol Vis S